EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
1-Hydroxy-Vitamin-D Treatment May Improve Outcomes in HOSPITALIZED PATIENTS WITH COVID-19, Reducing Composite Outcomes Including The Need For Additional Respiratory Support And In-Hospital Mortality . ...